Scalper1 News
Biogen Idec (BIIB), on the IBD 50 list of top-rated growth stocks, is working on a new oral drug for treating multiple sclerosis that has the potential for driving the biotech firm’s next generation of MS therapies, according to a research note from RBC Capital Markets. Little is known about the oral drug, which is in phase one trials. But in RBC’s note published on Sunday, analyst Michael Yee and his associates wrote that it could be a Scalper1 News
Scalper1 News